A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
June 17 (Reuters) – Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.
Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.
They would jointly develop and market the drug, MORAb-202, in Asia, Europe, the United States and Canada.
Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc (AGEN.O) to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.
The drugmaker has been betting on sales of its Opdivo drug to treat such cancers, in a market currently dominated by Merck & Co’s (MRK.N) rival treatment, Keytruda.
Eisai’s drug, MORAb-202, is being developed for the treatment of solid tumors, including ovarian, lung and breast cancers and is in the early stage of development.
Bristol-Myers will pay Eisai a royalty on sales outside of the collaboration territories, the companies said.Reporting by Amruta Khandekar; Editing by Vinay Dwivedi
Our Standards: The Thomson Reuters Trust Principles.
HALIFAX, NOVA SCOTIA — As Halifax confronts one of the most pressing housing shortages in…
PARIS, FRANCE — Servair, a member of gategroup, is once again reaching for the stars.…
Sale hailed as major sign of confidence in city’s real estate market and security in UAE …
By Daniel Welinder, Head of Aircraft Management and Sales at Jet Agent The acquisition of…
COPENHAGEN, DENMARK — DeCarbon Copenhagen 2026 will convene Europe’s biomass, carbon markets and digital infrastructure…
LONDON, UNITED KINGDOM — Parabellum Investments has announced the sale of business process outsourcing (BPO)…